Sejong Medical shareholders seeking to recover losses have called for a full investigation into alleged stock-price manipulation and solicitation to expedite approval of Genencell’s COVID-19 treatment trial, including the roles of Justice Minister nominee Kim Seung-won, Genencell founder Kang Se-chan, brokers Yang Mo and Yang Su-jin, and people affiliated with Kim’s office. The shareholders said approximately 30,000 investors suffered about 5 billion won in losses after buying shares on expectations surrounding Genencell’s treatment, clinical trials and public disclosures. The allegations form part of the broader "Oppagate" controversy involving Kim’s political contacts, political funds, property declarations and relationships with judges and brokers. Prosecutors deferred indictment against Kim in December 2024, citing no evidence that he received a direct financial benefit and uncertainty over whether the alleged solicitation was illegal, while the Seoul Western District Court found during Kang’s trial that Kim had pressed the Ministry of Food and Drug Safety to accelerate approval. Seoul Yeongdeungpo Police Station is investigating Kim’s alleged role, and the People Power Party and civic groups have sought parliamentary, special-counsel or other investigations. Shareholders also raised whistleblower-protection concerns after allegations that Democratic Party Supreme Council member Park Sun-won disclosed the identity of whistleblower Jo.